Policy Analysis
Security Boundaries and Cooperation Space in China–U.S. Biomedicine
On December 10, 2025, the U.S. House of Representatives passed the reconciled version of the Fiscal Year 2026 National Defense Authorization Act (NDAA). The defense policy bill authorizes approximately USD 901 billion in spending, approaching the USD 1 trillion mark.
The Rise of Chinese Innovative Drugs: How Can Hong Kong Seize the Opportunity
October 2025, at one of the most important conferences in European oncology—the “European Society for Medical Oncology Annual Meeting”—China delivered an impressive performance: 35 studies were selected for oral presentations, and three advanced to the highest-level“Presidential Sessions”.
China’s New Biomedical Regulation Changes the Game
China’s biomedical sector is undergoing a profound transformation.
